Twitter
Advertisement

Antibodies develop after second dose, got only first shot: Anil Vij after testing COVID positive

Vij tweeted that he had received only the first dose of the two-shot coronavirus vaccine developed by Bharat Biotech.

Latest News
article-main
FacebookTwitterWhatsappLinkedin

Haryana Home Minister Anil Vij who tested positive for Covid-19 on December 5 said on Sunday that he was told by doctors that antibodies take 14 days to build in the human body after the second dose of the vaccine.

Vij tweeted that he had received only the first dose of the two-shot coronavirus vaccine developed by Bharat Biotech. He was administered the first dose during the phase 3 trial of Bharat Biotech's coronavirus vaccine Covaxin.

"Before administering Covaxin, doctors told me that antibodies will develop after 14 days of the second dose... I am being treated at a civil hospital and I feel fine. It is only 14 days when I got the first shot," Vij tweeted in Hindi.

He also refuted a media report stating that he did not follow protocol despite being coronavirus positive. "A newspaper has published wrong and irresponsible news that I did not follow protocol despite being coronavirus positive and I continued meeting the people," Vij tweeted.

"This is false. After my report came out positive, I was admitted to Civil Hospital in Ambala Cantt within half an hour," read a tweet by Vij.

"Two days after coming from Panipat, when I was informed that the MLAs there had tested positive, I got the test done in Chandigarh the same day, which turned out negative," he said in a subsequent tweet.

Vij, who had received the first dose of Covaxin on November 20, is admitted to the Civil Hospital Ambala Cantt.

"All those who have come in close contact with me are advised to get themselves tested for corona," the minister tweeted. 

Meanwhile, Bharat Biotech said in a statement, "Covaxin clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days after the second dose. Covaxin has been designed to be efficacious when subjects receive both the doses."

According to the company, as part of the trial, 50% of the participants received the vaccine while the others were administered a placebo.

"The phase-3 trials are double-blinded and randomised, where 50% of subjects (participants in the trial) receive vaccines and 50% of subjects receive a placebo," it said.

Vij had offered to be the first volunteer in phase three human trials for the potential coronavirus vaccine Covaxin in which over 25,000 persons were administered trial doses. 

Bharat Biotech is developing the vaccine in collaboration with the National Institute of Virology (NIV) and the Indian Council of Medical Research (ICMR). It is among the several indigenous vaccines being developed in the country.

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed-  Follow DNA on WhatsApp.
Advertisement

Live tv

Advertisement
Advertisement